Replies to post #136905 on Biotech Values

[ilpapa]

I thought that several knowledgeable posters here had addressed the question of Watson's liability and had concluded that in practice it would be joint and several. As the deep pocket, Watson would effectively find itself at risk for A's misdeeds.
As to the billions (or less) of any potential award I don't have the background to form any sort of useful opinion

[DewDiligence]

[Craig Wheeler] did make note that there is another generic on the market right now. Who that is we don't know.

As of today, the participants in the US Lovenox market are SNY (branded and authorized generic), NVS, and Amphastar/WPI. If you thought there was someone else, you must have misunderstood what was said on the CC.